Search

Displaying results 7411 - 7420 of 8573 in total
  1. Drug

    Zevotrelvir

    go.drugbank.com/drugs/DB21638
    Experimental

    Zevotrelvir has a monoisotopic molecular weight of 537.2 Da.

  2. Drug

    Limnetrelvir

    go.drugbank.com/drugs/DB21677
    Experimental

    Limnetrelvir has a monoisotopic molecular weight of 557.17 Da.

  3. Drug

    Orenasitecan

    go.drugbank.com/drugs/DB21718
    Experimental

    Orenasitecan has a monoisotopic molecular weight of 1470.58 Da.

  4. Drug

    Epsametostat

    go.drugbank.com/drugs/DB21726
    Experimental

    Epsametostat has a monoisotopic molecular weight of 611.28 Da.

  5. Drug

    Mocaciclib

    go.drugbank.com/drugs/DB21730
    Experimental

    Mocaciclib has a monoisotopic molecular weight of 609.3 Da.

  6. Drug

    Cilansetron

    go.drugbank.com/drugs/DB04885
    Experimental

    Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

  7. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to

    Synonyms: [(11R,2'S)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol
  8. Drug

    3'-deoxyguanosine

    go.drugbank.com/drugs/DB03609
    Experimental

    These are compounds comprising a purine base attached to a sugar. This medication targets the protein purine nucleoside phosphorylase.

  9. Drug

    SC-236

    go.drugbank.com/drugs/DB14059
    Experimental

    SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374

  10. Drug

    Rocapuldencel-T

    go.drugbank.com/drugs/DB17588
    Investigational

    Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer